Stay updated with breaking news from Session Title. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational
23.05.2024 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that emerging Phase 1/2 clinical ... Seite 1
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--May 23, 2024--
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced the acceptance...